Navigation Links
InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
Date:8/20/2007

Diagnostic and Therapeutic Leaders Join Forces to Promote Early Detection

and Treatment of Hypertension in the UK

NEW YORK and MILTON KEYNES, United Kingdom, Aug. 20 /PRNewswire/ -- InterCure, Ltd. (Tel Aviv Stock Exchange: INCR), and Omron Healthcare (UK) Ltd., a wholly owned subsidiary of Omron Corporation, today announced an agreement to strengthen the link between hypertension diagnostics and therapies in the professional and pharmacy healthcare markets. The agreement combines marketing programs for Omron Healthcare's market-leading line of blood pressure monitoring systems in the United Kingdom and InterCure's RESPeRATE, the only medical device clinically proven to lower blood pressure through paced breathing therapy.

Omron Healthcare (UK) and InterCure have agreed to co-market their devices in the UK, with the goal of earlier detection and intervention for the 16 million people in the country suffering from hypertension. This will be done through a combination of efforts at leading conferences and tradeshows in the UK, with the most recent joint venture at the Primary Care Exhibition-the largest exhibition in the UK targeted towards primary care physicians.

In addition, as part of the alliance, Omron Corporation will include product information about RESPeRATE inside the boxes of its M10i product-Omron's premium blood pressure monitoring line available in the United Kingdom. InterCure will reciprocate with informational Omron product background in its RESPeRATE packaging.

Almost one billion people worldwide have high blood pressure, including 38 percent of people in the UK. Of those in the UK with hypertension, only 36 percent have their blood pressure under control. Traditional treatment methods of diet, exercise and medication are often unable to help patients reach their lower blood pressure goals. Left untreated, high blood pressure may lead to heart attack, stroke and kidney or heart failure.

"We welcome the support and collaboration of a leader in the UK blood pressure monitoring market as RESPeRATE expands its reach through broader channels," said Jon Collings, UK Country Manager of InterCure. "Omron's strength in the diagnostic market will help expand the presence of InterCure's revolutionary RESPeRATE technology within the UK, furthering our current efforts to provide a safe, alternative treatment option to hypertension patients worldwide."

"A marketing collaboration with InterCure complements our existing product offering in the hypertension marketplace within the United Kingdom," said Steve MacAleese, General Manager, Omron Healthcare (UK). "We understand the value of not only offering a modality to diagnose the issue but to also provide an innovative treatment option for hypertension patients."

About RESPeRATE

RESPeRATE(R) is FDA-cleared for over-the-counter sale and is the only medical device on the market clinically proven to lower blood pressure through paced breathing therapy. The device uses the body's natural tendency to follow external rhythms, interactively guiding the user to effortlessly reduce their breathing rate to a "therapeutic zone" of less than 10 breaths per minute. The breathing exercises with RESPeRATE relax the constricted muscles surrounding the small blood vessels, allowing the blood to flow more freely and yielding a significant and lasting reduction of blood pressure within weeks.

About InterCure, Ltd.

InterCure, a medical device company, publicly traded on the Tel Aviv Stock Exchange (TASE: INCR) has become a leader in the growing Personal Therapeutic Device category. Its broadly patented "device-guided breathing" technology platform enables a systematic reduction in sympathetic outflow of the autonomic nervous system. InterCure is successfully selling the world's first hypertension treatment device, RESPeRATE(R), with more than 75,000 units sold. With multiple published clinical studies, regulatory clearance in 10 key international markets (including FDA over-the-counter ("OTC") clearance in the U.S., the European CE mark and the Chinese SDA among others) and a renowned scientific advisory board, RESPeRATE is rapidly becoming a part of the standard of care for the treatment of hypertension. (http://www.intercure.com)

About Omron Healthcare Co., Ltd.

Omron Healthcare Co., Ltd. is a wholly owned subsidiary of Omron Corp and is based in Kyoto. A specialist firm in healthcare equipment for home and medical use, including digital blood pressure monitors, digital thermometers, body fat meters, and nebulizers, Omron Healthcare employs about 3,300 staff worldwide and recorded sales to March 2007 of 65.7 billion yen. Its president is Keiichiro Akahoshi.

Forward-Looking Statements

This news release may contain forward-looking statements that are based on the Company's current beliefs and assumptions and on information currently available to its management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result of these risks, uncertainties and other factors, readers are cautioned not to place undue reliance on any forward-looking statements included in this press release. These forward- looking statements represent beliefs and assumptions only as of the date of this news release, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.

Contacts:

Jane Hauser Brian Packard

Schwartz Communications InterCure, Inc.

781-684-0770 646-652-5800 x.7134

intercure@schwartz-pr.com bpackard@intercure.com


'/>"/>
SOURCE InterCure, Ltd.

Copyright©2007 PR Newswire.

Related biology technology :

1. Web-based reporting credited with states top healthcare ranking
2. Visions: Preizler offers insurers perspective on healthcare IT
3. Federal bill would set healthcare IT standards
4. IRS ruling could speed healthcare technology adoption
5. Bill would provide federal aid for healthcare IT
6. DHC 2007: Hayden says technology creates magic moment for healthcare delivery
7. Digital Healthcare Conference 2007: Mounting obstacles for health IT
8. Georgia healthcare system to install GEs radio frequency ID
9. GE Healthcare leads compact ultrasound market
10. CIO Leadership Series: Greg Smith, Wheaton Franciscan Healthcare
11. Merge Healthcare suffers $258M loss in `06
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Israel , March 27, 2017 DarioHealth ... with mobile health and big data solutions, today announced ... party insurance coverage option for U.S. consumers who want ... DarioHealth has signed strategic alliance agreements with ... verify insurance coverage benefits, and if approved, will supply ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... (hESC) Research - Global Strategic Business Report" report to their ... This ... Research in US$ Million. Annual estimates and forecasts are provided for ... from primary and secondary research. The report profiles ...
(Date:3/24/2017)... -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with ... today announced participation at the following conferences: ... Maidstone Life Sciences conference "Cancer Immunotherapy Conference" at the ... York, NY . Agenus will participate in three ... Robert B. Stein , M.D., Ph.D., President, R&D ...
(Date:3/23/2017)... 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW ... therapies for solid tumor cancers, today announced that ... it announced last Friday, March 17, 2017. ... investors securities totaling 28,843,692 shares, comprised of 18,843,692 ... shares of Class C Warrants pre-funded at the ...
Breaking Biology Technology:
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017  IBM ... Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, Home ... that will apply the power of IBM cognitive computing ... health centers. By analyzing data streaming from sensors in ... physical and environmental conditions, and obtain deeper learnings into ...
(Date:2/13/2017)... 2017  RSA Conference -- RSA, a Dell Technologies ... to enhance fraud detection and investigation across digital ... Fraud & Risk Intelligence Suite. The new platform ... insights from internal and external sources as well ... customers from targeted cybercrime attacks. "Fraudsters ...
(Date:2/8/2017)... Feb. 8, 2017 About Voice Recognition Biometrics ... match it against a stored voiceprint template. Acoustic ... cadence, and tone are compared to distinguish between ... installation, as most PCs already have a microphone ... Voice recognition biometrics are most likely to be ...
Breaking Biology News(10 mins):